Argent Advisors Inc. Buys Shares of 20,000 Heron Therapeutics, Inc. (NASDAQ:HRTX)

Argent Advisors Inc. acquired a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 20,000 shares of the biotechnology company’s stock, valued at approximately $31,000.

Several other hedge funds have also made changes to their positions in HRTX. Y Intercept Hong Kong Ltd purchased a new position in Heron Therapeutics in the third quarter valued at about $39,000. Capstone Investment Advisors LLC acquired a new position in Heron Therapeutics in the third quarter worth about $45,000. Cutter & CO Brokerage Inc. boosted its stake in Heron Therapeutics by 69.6% in the fourth quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 13,600 shares during the period. Glenmede Trust Co. NA boosted its stake in Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 10,578 shares during the period. Finally, Intech Investment Management LLC acquired a new position in shares of Heron Therapeutics during the third quarter worth approximately $72,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 8th. Needham & Company LLC reiterated a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, February 28th.

Heron Therapeutics Stock Up 3.0 %

Shares of HRTX opened at $2.39 on Tuesday. The stock has a market cap of $364.07 million, a price-to-earnings ratio of -13.28 and a beta of 1.55. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The company has a 50-day moving average price of $1.86 and a two-hundred day moving average price of $1.74.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million for the quarter, compared to analyst estimates of $37.37 million. Equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.